The Human Immunodeficiency Virus, commonly known as HIV, is a retrovirus that targets the human immune system, specifically destroying CD4+ T-lymphocytes. These cells act as the chief coordinators of the body's immune defense, signaling other cells to fight off infections. As the virus replicates, it steadily depletes the count of these vital cells, leaving the individual vulnerable to opportunistic infections and specific malignancies. Transmission occurs primarily through unprotected sexual intercourse, exposure to infected blood or blood products, and vertical transmission from mother to child during pregnancy, childbirth, or breastfeeding. In Nigerian clinical practice, understanding these modes of transmission forms the cornerstone of effective public health education and community sensitization.
Once HIV enters the human body, it binds to surface receptors on host cells, enters the cell, and uses an enzyme called reverse transcriptase to convert its viral RNA into DNA. This viral DNA integrates into the host's genetic material, turning the host cell into a factory for producing more viruses. The infection progresses through distinct phases, ranging from acute seroconversion illness to a prolonged clinical latency period, and finally advancing to Acquired Immunodeficiency Syndrome (AIDS) when the CD4 count drops severely or defining illnesses appear.
Oncogenic viruses are infectious agents capable of causing cancer in humans. Unlike typical lytic viruses that destroy host cells quickly, oncogenic viruses alter host cell DNA, forcing abnormal, uncontrolled cell division.
People living with HIV face a much higher risk of developing virus-induced cancers compared to the general population. Because HIV destroys CD4+ cells and weakens overall immune surveillance, the body loses its ability to clear secondary viral infections like HPV, EBV, and Hepatitis viruses. Consequently, these oncogenic viruses persist unchecked, multiplying their transforming effects on host tissues and accelerating the progression from persistent infection to overt malignancy.
The intersection of HIV and oncogenic viruses gives rise to specific cancers categorized as AIDS-defining illnesses. Among the most prominent is Kaposi sarcoma, a tumor of the blood vessel walls driven by Human Herpesvirus 8 (HHV-8), presenting as distinctive purplish skin or mucosal lesions. Another frequent complication is cervical cancer, driven by persistent high-risk HPV strains in women living with HIV. Additionally, various forms of non-Hodgkin lymphoma, linked closely to Epstein-Barr virus activity, occur with increased frequency and aggressiveness in severely immunocompromised patients.
Midwives play a frontline role in mitigating the impact of HIV and oncogenic co-infections, particularly among women of reproductive age. Routine antenatal care provides an ideal window for Opt-out HIV counseling and testing, enabling prompt initiation of Antiretroviral Therapy (ART) to achieve viral suppression and prevent mother-to-child transmission. Furthermore, midwives should champion preventative interventions such as HPV vaccination for adolescent girls and promote regular cervical cancer screening through visual inspection with acetic acid or Pap smears for all eligible women attending clinics.